02.01.23
Aprecia Pharmaceuticals has named Owen Murray as its new CEO. Murray will lead the expansion of Aprecia's offerings in proprietary 3D-printed (3DP) pharmaceutical technologies.
"Owen has a unique background in both healthcare innovation and pharmaceutical commercialization,” said E. Thomas Arington, chairman, Aprecia. “His expertise will position Aprecia to further capitalize on exciting growth opportunities, by bringing value to partners and solutions to the unmet needs of patients around the world.”
Murray most recently served as the vice president of North American technical operations and quality assurance at Recordati Rare Diseases in New Jersey. Prior to joining Recordati, he held varying positions of increasing responsibility at Cardinal Health, Lundbeck, and Ovation Pharmaceuticals in Europe and the U.S. Murray has more than 25 years of experience in pharmaceutical and healthcare businesses, ranging from early product development through commercialization. He has successfully developed and led R&D, operations, supply chain, and quality operations teams.
"Owen has a unique background in both healthcare innovation and pharmaceutical commercialization,” said E. Thomas Arington, chairman, Aprecia. “His expertise will position Aprecia to further capitalize on exciting growth opportunities, by bringing value to partners and solutions to the unmet needs of patients around the world.”
Murray most recently served as the vice president of North American technical operations and quality assurance at Recordati Rare Diseases in New Jersey. Prior to joining Recordati, he held varying positions of increasing responsibility at Cardinal Health, Lundbeck, and Ovation Pharmaceuticals in Europe and the U.S. Murray has more than 25 years of experience in pharmaceutical and healthcare businesses, ranging from early product development through commercialization. He has successfully developed and led R&D, operations, supply chain, and quality operations teams.
